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summaries
pharmacoGenetics
Effect of genetic alterations of cytarabine-
metabolizing enzymes in childhood acute 
lymphoblastic leukemia
In 94 children with ALL and LL, Banklaui and coll
leagues found an increased risk of mucositis after treatl
ment with lowldose cytarabine in patients with the 
cytarabinelmetabolizing allele dCKl360G. Neither the 
dCK or CDA polymorphisms affected minimal residual 
disease status at the end of the induction phase. 
proGnostic factors
Prognostic effect of hormone receptor status in 
early HER2 positive breast cancer patients
Gómez and colleagues found statistically significant difl
ferences in diseaselfree survival but not overall survival 
between HRlpositive and HRlnegative HER2lpositive 
breast cancer patients treated with surgery and stanl
dard chemotherapy.
antiViral therapY
High efficacy and low toxicity of short-course 
oral valganciclovir as pre-emptive therapy for 
hematopoietic stem cell transplant cytomegalovirus 
infection
Saleh and colleagues treated 47 CMVlpositive HSCT 
outpatients with 900 mg twice daily of valganciclovir. 
Complete responses of 92% and 97% were received afl
ter 1 and 2 weeks of therapy. Only 3% of episodes were 
considered refractory and required alternative therapy. 
Neutropenia was the main toxicity, requiring GlCSF 
in 8 episodes. “Shortlcourse oral VGC” seems highly 
effective with minimal toxicity but large, randomized 
trials are necessary for validation.
cancer chemotherapY
Poor survival outcome of docetaxel every three 
weeks plus prednisone for treatment of patients 
with hormone-refractory metastatic prostate 
cancer
In 35 patients with HRMPC, AbulHamer and  coll
leagues observed an overall tumor response rate of 
74.3% and no patients achieved a complete response, 
which is similar to other reports. The median overall 
survival of 15 months was less than in other reports, but 
the study population was of high risk and had a poor 
prognosis.
Improved survival with combined chemo-
radiotherapy in primary central nervous system 
lymphoma
In a retrospective analysis, Abdelsalam and colleagues 
found that of 16 of 52 patients who had combined 
modality therapy (highldose methotrexate followed 
by whole brain irradiation) had a better outcome than 
36 who had only whole brain irraditation. Multivariate 
analysis failed to identify any prognostic factors.
